BriaCell ($BCTX) receives FDA clearance for Bria-PROS+, its next-generation personalized immunotherapy for prostate cancer, clearing the path for a Phase 1/2a study.
News: https://bit.ly/4pX8Grz
#Biotech #CancerImmunotherapy #ProstateCancer #HealthcareStocks